BS_6MZ7FRZH
Supratentorial Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Supratentorial Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Supratentorial Ependymoma
- overall_survival_months
- 36.925098554533506
- age_years
- 0.605
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.560
- E2F_TARGETS+0.453
- G2M_CHECKPOINT+0.421
- NOTCH_SIGNALING+0.380
- DNA_REPAIR+0.371
- INTERFERON_GAMMA_RESPONSE+0.307
- WNT_BETA_CATENIN_SIGNALING+0.306
- MYC_TARGETS_V1+0.193
- SPERMATOGENESIS+0.190
- PI3K_AKT_MTOR_SIGNALING+0.141
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.345
- MYOGENESIS-0.296
- KRAS_SIGNALING_UP-0.294
- TNFA_SIGNALING_VIA_NFKB-0.279
- APICAL_JUNCTION-0.241
- COAGULATION-0.235
- HYPOXIA-0.231
- COMPLEMENT-0.228
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.214
- IL6_JAK_STAT3_SIGNALING-0.213
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_6MZ7FRZH | EPN | Supratentorial EPN | 0.874 |
| 2 | SRR33532781 | — | D | 0.767 |
| 3 | BS_TGS109T3 | high-grade glioma | — | 0.755 |
| 4 | MNG274 | — | — | 0.753 |
| 5 | TCGA-RS-A6TP-01A-12R-A34R-07 | — | — | 0.735 |
| 6 | TCGA-AN-A0XR-01A-11R-A109-07 | — | B | 0.731 |
| 7 | BS_EK5PCKY0 | Supratentorial Ependymoma | — | 0.727 |
| 8 | BS_N5DVEJXT | Supratentorial Ependymoma | — | 0.725 |
| 9 | TCGA-H4-A2HQ-01A-11R-A180-07 | — | — | 0.708 |
| 10 | SRR934887 | — | — | 0.704 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.453 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.421 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.371 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.307 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.306 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.193 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.141 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.115 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.088 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.038 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.036 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.023 | Temsirolimus | — uncovered |
| PEROXISOME | 0.023 | Idelalisib | — uncovered |